Viatris EBITDA 2010-2025 | VTRS

Viatris annual and quarterly EBITDA history from 2010 to 2025. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
  • Viatris EBITDA for the quarter ending March 31, 2025 was $0.719B, a 19.62% decline year-over-year.
  • Viatris EBITDA for the twelve months ending March 31, 2025 was $2.728B, a 16.63% decline year-over-year.
  • Viatris 2024 annual EBITDA was $2.903B, a 17.21% decline from 2023.
  • Viatris 2023 annual EBITDA was $3.507B, a 24.47% decline from 2022.
  • Viatris 2022 annual EBITDA was $4.643B, a 3.8% increase from 2021.
Viatris Annual EBITDA
(Millions of US $)
2024 $2,903
2023 $3,507
2022 $4,643
2021 $4,473
2020 $2,005
2019 $2,735
2018 $3,016
2017 $3,243
2016 $2,222
2015 $2,493
2014 $1,919
2013 $1,652
2012 $1,656
2011 $1,516
2010 $1,144
2009 $925
Viatris Quarterly EBITDA
(Millions of US $)
2025-03-31 $719
2024-12-31 $566
2024-09-30 $896
2024-06-30 $546
2024-03-31 $895
2023-12-31 $190
2023-09-30 $1,131
2023-06-30 $1,056
2023-03-31 $1,130
2022-12-31 $668
2022-09-30 $1,260
2022-06-30 $1,271
2022-03-31 $1,443
2021-12-31 $672
2021-09-30 $1,375
2021-06-30 $1,269
2021-03-31 $1,156
2020-12-31 $72
2020-09-30 $784
2020-06-30 $550
2020-03-31 $600
2019-12-31 $820
2019-09-30 $793
2019-06-30 $597
2019-03-31 $525
2018-12-31 $842
2018-09-30 $839
2018-06-30 $681
2018-03-31 $654
2017-12-31 $945
2017-09-30 $760
2017-06-30 $895
2017-03-31 $643
2016-12-31 $790
2016-09-30 $315
2016-06-30 $714
2016-03-31 $403
2015-12-31 $765
2015-09-30 $859
2015-06-30 $535
2015-03-31 $334
2014-12-31 $561
2014-09-30 $629
2014-06-30 $355
2014-03-31 $374
2013-12-31 $415
2013-09-30 $467
2013-06-30 $427
2013-03-31 $343
2012-12-31 $391
2012-09-30 $506
2012-06-30 $384
2012-03-31 $374
2011-12-31 $372
2011-09-30 $407
2011-06-30 $406
2011-03-31 $331
2010-12-31 $207
2010-09-30 $339
2010-06-30 $297
2010-03-31 $301
2009-12-31 $164
2009-09-30 $165
2009-06-30 $273
2009-03-31 $322
Sector Industry Market Cap Revenue
Medical Medical Services $10.610B $14.739B
Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise.
Stock Name Country Market Cap PE Ratio
Danaher (DHR) United States $145.009B 27.20
Elevance Health (ELV) United States $86.741B 11.19
CVS Health (CVS) United States $81.290B 10.10
Cencora (COR) United States $55.092B 19.17
DiDi Global (DIDIY) China $23.485B 35.64
Natera (NTRA) United States $22.560B 0.00
BioMerieux (BMXMF) France $16.856B 0.00
Solventum (SOLV) United States $13.071B 13.84
EUROFINS SCIENT (ERFSF) Luxembourg $13.026B 0.00
ICON (ICLR) Ireland $11.688B 10.87
Revvity (RVTY) United States $11.345B 19.52
CochLear (CHEOY) Australia $11.134B 0.00
Doximity (DOCS) United States $10.995B 50.90
Avantor (AVTR) United States $9.329B 13.55
HealthEquity (HQY) United States $9.272B 40.61
Medpace Holdings (MEDP) United States $8.792B 23.35
Sonic Healthcare (SKHHY) Australia $8.450B 0.00
Charles River Laboratories (CRL) United States $7.416B 14.53
Amplifon S.p.A (AMFPF) Italy $5.378B 29.44
Bausch + Lomb (BLCO) Canada $4.450B 26.21
BrightSpring Health Services (BTSG) United States $3.875B 35.87
Sotera Health (SHC) United States $3.491B 19.84
Surgery Partners (SGRY) United States $2.989B 38.87
Alignment Healthcare (ALHC) United States $2.898B 0.00
Concentras Parent (CON) United States $2.816B 16.27
Organon (OGN) United States $2.610B 2.77
GeneDx Holdings (WGS) United States $1.983B 76.39
Progyny (PGNY) United States $1.923B 42.32
Ardent Health Partners (ARDT) United States $1.920B 8.18
Premier (PINC) United States $1.884B 14.30
PACS (PACS) United States $1.629B 0.00
GoodRx Holdings (GDRX) United States $1.622B 32.43
Teladoc Health (TDOC) United States $1.298B 0.00
Pediatrix Medical (MD) United States $1.213B 9.23
Establishment Labs Holdings (ESTA) $1.124B 0.00
CareDx (CDNA) United States $1.105B 17.26
Ryman Healthcare (RYHTY) New Zealand $1.011B 0.00
Agilon Health (AGL) United States $0.944B 0.00
AMN Healthcare Services Inc (AMN) United States $0.843B 7.89
QDM (QDMI) Hong Kong, SAR China $0.752B 0.00
Nutex Health (NUTX) United States $0.651B 9.85
Embecta (EMBC) United States $0.592B 3.99
LifeMD (LFMD) United States $0.553B 0.00
Enhabit (EHAB) United States $0.543B 44.67
InnovAge Holding (INNV) United States $0.514B 0.00
SBC Medicals (SBC) United States $0.495B 0.00
Sonida Senior Living (SNDA) United States $0.474B 0.00
Auna S.A (AUNA) Luxembourg $0.470B 10.58
COMPASS Pathways (CMPS) United Kingdom $0.445B 0.00
Performant Healthcare (PHLT) United States $0.258B 0.00
Oncology Institute (TOI) United States $0.237B 0.00
Beauty Health (SKIN) United States $0.202B 0.00
DocGo (DCGO) United States $0.156B 25.50
KindlyMD (KDLY) United States $0.150B 0.00
Pheton Holdings (PTHL) China $0.104B 0.00
So-Young (SY) China $0.090B 0.00
OncoCyte (OCX) United States $0.079B 0.00
Basel Medical Group (BMGL) Singapore $0.075B 0.00
KindlyMD (NAKA) United States $0.070B 0.00
Ascend Wellness Holdings (AAWH) United States $0.060B 0.00
NeueHealth (NEUE) United States $0.060B 0.00
IceCure Medical (ICCM) Israel $0.057B 0.00
Sera Prognostics (SERA) United States $0.056B 0.00
Biodesix (BDSX) United States $0.048B 0.00
ModivCare (MODV) United States $0.047B 0.00
NeuroOne Medical Technologies (NMTC) United States $0.029B 0.00
SeaStar Medical Holding (ICU) United States $0.013B 0.00
Intelligent Bio Solutions (INBS) United States $0.013B 0.00
Co-Diagnostics (CODX) United States $0.010B 0.00
BioNexus Gene Lab (BGLC) $0.006B 0.00
XWELL (XWEL) United States $0.005B 0.00
Aclarion (ACON) United States $0.004B 0.00
ISpecimen (ISPC) United States $0.003B 0.00
INVO Fertility (IVF) United States $0.003B 0.00
NewGenIvf Group (NIVF) Thailand $0.001B 0.00
Cano Health (CANOQ) United States $0.000B 0.00